News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Philadelphia Cell and Gene Therapy Jobs More Than Doubled in Less Than Three Years
As the number of gene and cell therapy jobs continue to grow, Philadelphia continues to attract diverse pools of talent.
Penn spinout Verismo Therapeutics Makes Agreement to Fund University Research of KIR-CAR platform of Car-T to Target Solid Tumors
Learn about Penn spinout Verismo Therapeutics' agreement to fund four years of university research of KIR-CAR platform of Car-T to target solid tumors.
Pharma Companies Search for Solutions in the Face of Upcoming Patent Cliff
Read about the current state of the biopharma industry in the face of pending patent cliff.
Carisma Therapeutics continues to thrive and expand
Penn and Carisma Therapeutics (Carisma) have strengthened the intellectual property portfolio covering this technology with the issuance of five additional patents in 2022.
Staff Spotlight: Meet PCI’s Newest Team Members
Meet PCI's newest staff members and read their bios.
The Future of Research-Based Innovation Hubs with the Rise of Remote Work
John Swartley and Bhavana Mohanraj discuss how working remotely will impact research and innovation hubs.
Car-T Pioneer Bruce Levine Speaks on the Past, Present and Future of Cancer Therapy
Learn about Dr. Bruce Levine's predictions for the future uses of Car-T therapy.
Penn ICorps Graduate and President’s Innovation Prize Winner Strella Biotech Raises $8 Million in Series A Funding Round
Read about how this Philadelphia-based agricultural biotech startup received funding from Mark Cuban, Google Ventures, and others.
Gnubiotics and Penn Explore CAR-T Therapy
This collaboration will take place through company-sponsored pre-clinical research studies in the laboratory of Avery Posey, PhD, an assistant professor at the Perelman School of Medicine.
Penn Medicine Co-Investment Program continues to thrive
Fiscal year 2022 saw the Co-Investment Program help launch and fund 2 new companies ViTToria Biotherapeutics and Dispatch Bio, as well as participate in follow-on rounds for Linnaeus Therapeutics, Car